These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 11915890)
1. Hormone replacement therapy and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Feeman W Circulation; 2002 Mar; 105(12):e71. PubMed ID: 11915890 [No Abstract] [Full Text] [Related]
2. Hormone replacement therapy and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Genazzani AR Circulation; 2002 Mar; 105(12):e71. PubMed ID: 11914267 [No Abstract] [Full Text] [Related]
3. [Hormonal treatment for menopause and arterial risk]. Gueyffier F; Cornu C Rev Prat; 2005 Feb; 55(4):383-8. PubMed ID: 15828616 [TBL] [Abstract][Full Text] [Related]
4. [Hormone replacement therapy in menopause and cardiovascular disease--one more time]. Os I; Tonstad S Tidsskr Nor Laegeforen; 2002 Aug; 122(18):1808-10. PubMed ID: 12362695 [No Abstract] [Full Text] [Related]
6. Hormone replacement therapy in menopause and lung cancer: an update. La Vecchia C Eur J Cancer Prev; 2006 Jun; 15(3):189-90. PubMed ID: 16679859 [No Abstract] [Full Text] [Related]
8. Statement on results of the HERS II trial on hormone replacement therapy. American College of Obstetricians and Gynecologists Ginecol Obstet Mex; 2002 Aug; 70():406-8. PubMed ID: 12448046 [No Abstract] [Full Text] [Related]
10. [Hormone therapy during menopause and risk of cardiovascular disease]. Pedersen AT; Ottesen BS Ugeskr Laeger; 2002 Apr; 164(18):2414. PubMed ID: 12024849 [No Abstract] [Full Text] [Related]
11. Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden. Shah NR Cancer; 2003 Oct; 98(7):1552-3; author reply 1553. PubMed ID: 14508845 [No Abstract] [Full Text] [Related]
12. Hormone replacement therapy post Women's Health Initiative study: where do we stand? Calleja-Agius J; Brincat MP Curr Opin Obstet Gynecol; 2008 Dec; 20(6):513-8. PubMed ID: 18989125 [TBL] [Abstract][Full Text] [Related]
13. Rationale for low-dose systemic hormone replacement therapy and review of estradiol 0.5 mg/NETA 0.1 mg. Johansen OE; Qvigstad E Adv Ther; 2008 Jun; 25(6):525-51. PubMed ID: 18568306 [TBL] [Abstract][Full Text] [Related]
14. Hormone replacement therapy--is there a place for its use in neurology? Vuković V; Lovrencić-Huzjan A; Solter VV; Dordević V; Demarin V Coll Antropol; 2003 Jun; 27(1):413-24. PubMed ID: 12974172 [TBL] [Abstract][Full Text] [Related]
15. [Hormone therapy and cardiovascular disease after menopause. Myths and realities]. Skouby SO Ugeskr Laeger; 2003 Oct; 165(41):3907. PubMed ID: 14579549 [No Abstract] [Full Text] [Related]
16. Postmenopausal hormone therapy and the risk of cardiovascular disease. Bittner V Expert Opin Pharmacother; 2009 Sep; 10(13):2041-53. PubMed ID: 19563274 [TBL] [Abstract][Full Text] [Related]
18. Baseline characteristics of menopausal women with coronary heart disease in cardiovascular outcomes clinical trials of menopausal hormone therapy or raloxifene. Wenger NK; Geiger MJ Contemp Clin Trials; 2005 Dec; 26(6):612-5. PubMed ID: 16257585 [TBL] [Abstract][Full Text] [Related]
19. Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. Klein S; Burke LE; Bray GA; Blair S; Allison DB; Pi-Sunyer X; Hong Y; Eckel RH; Circulation; 2004 Nov; 110(18):2952-67. PubMed ID: 15509809 [TBL] [Abstract][Full Text] [Related]